Nasdaq · Healthcare
CORCEPT THERAPEUTICS INC (CORT)
As-reported financials and recent SEC filings for CORCEPT THERAPEUTICS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$761.4M
Net income
$99.7M
Net margin
13.1%
Diluted EPS
$0.82
ROE
15.4%
P/E (TTM)
249.5×
Market cap
$9.37B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M |
| Diluted EPS | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →8-K2026-06-17
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-16
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-04
View on EDGAR →42026-06-03
View on EDGAR →Go deeper on CORT
Search CORCEPT THERAPEUTICS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.